Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume 17, Issue 12, Pages 1180-1193
Publisher
Wiley
Online
2015-09-07
DOI
10.1111/dom.12572
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study
- (2015) Rimei Nishimura et al. Cardiovascular Diabetology
- SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
- (2015) Silvio E Inzucchi et al. Diabetes & Vascular Disease Research
- Correlates of Aortic Stiffness Progression in Patients With Type 2 Diabetes: Importance of Glycemic Control
- (2015) Marcel T. Ferreira et al. DIABETES CARE
- Association between pulse pressure and risk of hospital admissions for cardiovascular events among people with Type 2 diabetes: a population-based case-control study
- (2015) D. Yu et al. DIABETIC MEDICINE
- The relationship between arterial stiffness and heart failure with preserved ejection fraction: a systemic meta-analysis
- (2015) Bryan Chow et al. HEART FAILURE REVIEWS
- Differential associations of central and brachial blood pressure with carotid atherosclerosis and microvascular complications in patients with type 2 diabetes
- (2014) Chan-Hee Jung et al. BMC Cardiovascular Disorders
- Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
- (2014) Bernard Zinman et al. Cardiovascular Diabetology
- The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
- (2014) David ZI Cherney et al. Cardiovascular Diabetology
- Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice
- (2014) Bowen Lin et al. Cardiovascular Diabetology
- ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD – Summary
- (2014) Diabetes & Vascular Disease Research
- Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
- (2014) Hans-Ulrich Häring et al. DIABETES CARE
- Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
- (2014) Ilkka Tikkanen et al. DIABETES CARE
- Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis
- (2014) William L. Baker et al. Journal of the American Society of Hypertension
- The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity
- (2014) Matthias Oelze et al. PLoS One
- Meta-Analysis of the Quantitative Relation Between Pulse Pressure and Mean Arterial Pressure and Cardiovascular Risk in Patients With Diabetes Mellitus
- (2013) Satoru Kodama et al. AMERICAN JOURNAL OF CARDIOLOGY
- Advanced glycation end products accelerate rat vascular calcification through RAGE/oxidative stress
- (2013) Qin Wei et al. BMC Cardiovascular Disorders
- Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial
- (2013) H.-U. Haring et al. DIABETES CARE
- Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial
- (2013) C. S. Kovacs et al. DIABETES OBESITY & METABOLISM
- Type 2 Diabetes Mellitus and Hypertension
- (2013) Guido Lastra et al. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
- Early vascular ageing in translation
- (2013) Peter M. Nilsson et al. JOURNAL OF HYPERTENSION
- Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
- (2013) Michael Roden et al. Lancet Diabetes & Endocrinology
- Predictive Value for Mortality of the Double Product at Rest Obtained by Home Blood Pressure Measurement: The Ohasama Study
- (2012) R. Inoue et al. AMERICAN JOURNAL OF HYPERTENSION
- Ambulatory arterial stiffness index: A systematic review and meta-analysis
- (2012) Anastasios Kollias et al. ATHEROSCLEROSIS
- Elastin in Large Artery Stiffness and Hypertension
- (2012) Jessica E. Wagenseil et al. Journal of Cardiovascular Translational Research
- Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
- (2011) R. Grempler et al. DIABETES OBESITY & METABOLISM
- Renin-Angiotensin-Aldosterone System in Diabetes and Hypertension
- (2011) Willa A. Hsueh et al. Journal of Clinical Hypertension
- Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis
- (2010) C. Vlachopoulos et al. EUROPEAN HEART JOURNAL
- Arterial Destiffening With Weight Loss in Overweight and Obese Middle-Aged and Older Adults
- (2010) A. Laura Dengo et al. HYPERTENSION
- Prediction of Cardiovascular Events and All-Cause Mortality With Arterial Stiffness
- (2010) Charalambos Vlachopoulos et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
- (2010) The Emerging Risk Factors Collaboration LANCET
- Pulse pressure strongly predicts cardiovascular disease risk in patients with type 2 diabetes from the Swedish National Diabetes Register (NDR)
- (2009) P.M. Nilsson et al. DIABETES & METABOLISM
- Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease
- (2008) C. D. A. Stehouwer et al. DIABETOLOGIA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search